Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-DECISION: Discontinuation of β-blocker Therapy After AMI
NCT04769362Phase 4Recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2021
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in myocardial infarction (MI) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Major adverse cardiac events at 2.5 years. Started May 2021; status: recruiting.
02
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04769362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769362.